| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Aconicarchamine B, as a C20-diterpenoid alkaloid from Aconitum species, may exert its biological effects through multiple targets including ion channels (sodium, potassium, calcium channels), neurotransmitter receptors, and signaling pathways involved in inflammation and cancer. Aconitum alkaloids are known for their cardiotonic, analgesic, and anti-inflammatory activities. The compound's diverse pharmacological effects include cardiotonic, analgesic, antihypertensive, hypoglycemic, anti-inflammatory, and antitumor activities.
|
|---|---|
| ln Vitro |
In vitro, Aconicarchamine B has been studied for its various pharmacological activities. As a C20-diterpenoid alkaloid, it exhibits cardiotonic, analgesic, anti-inflammatory, and antitumor effects in cellular assays. The compound's activity is concentration-dependent. However, specific in vitro activity data for Aconicarchamine B are limited. The compound is primarily used as a natural product standard for research purposes.
|
| ln Vivo |
In vivo, Aconicarchamine B has been reported to exhibit various pharmacological activities including cardiotonic, analgesic, antihypertensive, hypoglycemic, anti-inflammatory, antitumor, anti-hypoxic, anti-arrhythmic, and immunomodulatory effects. However, detailed in vivo efficacy data are limited. The compound is primarily used as a research tool for studying the pharmacology of Aconitum alkaloids.
|
| Enzyme Assay |
Non-cell-based assays for Aconicarchamine B involve characterization of its chemical properties. The compound's structure is confirmed by NMR and MS. Its purity is determined by HPLC. The compound's chemical properties including molecular formula (C₃₁H₄₁NO₇) and molecular weight (539.66) are characterized. Its solubility and stability are characterized for research applications.
|
| Cell Assay |
Cellular assays for Aconicarchamine B are performed using various cell lines. Cells are treated with the compound at various concentrations, and cellular responses are measured. Cell viability is measured by MTT assays. Anti-inflammatory activity is evaluated by measuring pro-inflammatory cytokine production and NF-κB activation. Anticancer activity is assessed by measuring cell proliferation and apoptosis. Cardiotonic effects may be evaluated in cardiomyocyte models.
|
| Animal Protocol |
In vivo experiments with Aconicarchamine B are conducted in animal models to evaluate its various pharmacological activities. Animal models of pain, inflammation, cancer, cardiovascular disease, and diabetes may be used. Animals are treated with the compound via oral or intraperitoneal administration, and disease parameters are measured. However, detailed in vivo data are limited. The compound is for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Aconicarchamine B have not been extensively characterized. As a diterpenoid alkaloid with a molecular weight of 539.66, the compound is expected to have moderate oral bioavailability and good tissue penetration. Its absorption, distribution, metabolism, and excretion are not well-defined. Comprehensive PK studies are needed to support further development.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Aconicarchamine B has not been comprehensively evaluated. Aconitum alkaloids are known to be toxic, with cardiotoxic and neurotoxic effects at high doses. The compound's safety profile, including genotoxicity, organ toxicity, and maximum tolerated dose, has not been fully characterized. The compound is for research use only and is not intended for human consumption.
|
| References | |
| Additional Infomation |
Aconicarchamine B (CAS# 1275535-67-5) is a C20-diterpenoid alkaloid with the molecular formula C₃₁H₄₁NO₇ and a molecular weight of 539.66. It is isolated from Aconitum carmichaelii (Fuzi). The compound has been reported to exhibit various pharmacological activities including cardiotonic, analgesic, antihypertensive, hypoglycemic, anti-inflammatory, antitumor, anti-hypoxic, anti-arrhythmic, and immunomodulatory effects. As of current knowledge, Aconicarchamine B is not approved as a therapeutic agent.
|
| Molecular Formula |
C31H41NO7
|
|---|---|
| Molecular Weight |
539.66
|
| Exact Mass |
541.303
|
| CAS # |
1275535-67-5
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3
|
| SMILES |
CCN1C[C@@]23[C@H](CC[C@]45[C@H]2[C@H]([C@H](CC4)[C@]([C@@H]5OC(=O)C)(COC(=O)C6=CC=CC=C6)O)O)C(C1)(CC[C@@H]3O)C
|
| InChi Key |
XNEDEYYIWURZGN-JKIMNVFXSA-N
|
| InChi Code |
InChI=1S/C31H43NO7/c1-4-32-16-28(3)13-12-23(34)30(17-32)22(28)11-15-29-14-10-21(24(35)25(29)30)31(37,27(29)39-19(2)33)18-38-26(36)20-8-6-5-7-9-20/h5-9,21-25,27,34-35,37H,4,10-18H2,1-3H3/t21-,22+,23-,24-,25+,27+,28?,29-,30-,31-/m0/s1
|
| Chemical Name |
[(1R,2R,3R,4S,5R,6R,7R,10R,15S)-6-acetyloxy-13-ethyl-3,5,15-trihydroxy-11-methyl-13-azapentacyclo[9.3.3.24,7.01,10.02,7]nonadecan-5-yl]methyl benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8530 mL | 9.2651 mL | 18.5302 mL | |
| 5 mM | 0.3706 mL | 1.8530 mL | 3.7060 mL | |
| 10 mM | 0.1853 mL | 0.9265 mL | 1.8530 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
